PROTOKINETIX, INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0164 USD | +4.93% |
|
+5.13% | -13.68% |
| Mar. 29 | ProtoKinetix, Incorporated announced a financing transaction | CI |
| Mar. 20 | ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 6.58M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | - | EV / Sales 2022 | - |
| Net cash position 2022 | 25.55K | Net cash position 2023 | 20.41K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.29
x | P/E ratio 2023 |
-1.9
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +4.93% | ||
| 1 week | +5.13% | ||
| Current month | +2.50% | ||
| 1 month | +7.89% | ||
| 3 months | -18.00% | ||
| 6 months | -5.75% | ||
| Current year | -13.68% |
1 week
0.02
0.02
1 month
0.010.02
Current year
0.010.02
1 year
0.010.03
3 years
0.010.20
5 years
0.010.32
10 years
0.010.32
| Managers | Title | Age | Since |
|---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 14-05-31 |
Michael Guzzetta
DFI | Director of Finance/CFO | 66 | 17-11-13 |
Victoria Bantz
LAW | General Counsel | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clarence Smith
CEO | Chief Executive Officer | 60 | 14-05-31 |
Edward McDonough
BRD | Director/Board Member | 71 | 15-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 0.0164 | +4.93% | 6,700 |
Delayed Quote OTC Markets, May 09, 2024 at 01:58 pm EDT
More quotes
ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.68% | 5.79M | |
| +26.37% | 48.16B | |
| -1.01% | 41.73B | |
| +41.82% | 41.03B | |
| -5.31% | 28.77B | |
| +9.34% | 25.59B | |
| -21.69% | 18.96B | |
| +6.23% | 12.92B | |
| +26.99% | 12.03B | |
| -3.38% | 11.77B |
- Stock Market
- Equities
- PKTX Stock
